Shionogi

Shionogi Initiates Global Phase 2 Trial for Pompe Disease Drug S-606001

Shionogi & Co., Ltd. has commenced a global Phase 2 clinical trial for S-606001, an investigational treatment for Pompe disease. This trial will evaluate the safety and efficacy of S-606001 in patients with Pompe disease across multiple international sites. The initiation of this trial represents a crucial step in the development of a potential new therapy for this rare genetic disorder.

Shionogi Applies for KorecTive® Lotion Approval in Japan

Shionogi & Co., Ltd. announced that a manufacturing and sales marketing approval application has been submitted in Japan for an additional lotion formulation of KorecTive®, a treatment for atopic dermatitis. This submission aims to expand the therapeutic options for patients by offering a new dosage form, potentially increasing market penetration and patient convenience.

Shionogi and Hitachi Launch AI for Drug Regulatory Document Creation

Shionogi & Co., Ltd. and Hitachi, Ltd. have launched a solution utilizing generative AI to support the creation of regulatory documents in drug development. This new system is designed to significantly streamline the process, aiming to reduce document creation time by up to 50%. By leveraging AI, the companies intend to enhance the efficiency of pharmaceutical development and accelerate the submission of new drugs.